BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15939585)

  • 1. Aromatase inhibitors for therapy of advanced breast cancer.
    Ingle JN; Suman VJ
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):113-9. PubMed ID: 15939585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
    de Jong PC; Blijham GH
    Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
    Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors for breast cancer in postmenopausal women.
    Campos SM
    Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
    Nabholtz JM; Gligorov J
    Rev Recent Clin Trials; 2006 Sep; 1(3):237-49. PubMed ID: 18473976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New generation aromatase inhibitors--from the advanced to the adjuvant setting.
    Buzdar AU
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S13-7; discussion S33-5. PubMed ID: 12353818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
    Allred DC; Baum M; Buzdar AU; Carlson RW; Dowsett M; Elledge RM; Gradishar WJ; Grana G; Howell A; Mamounas EP
    Breast J; 2003; 9(3):213-22. PubMed ID: 12752630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    Sainsbury R
    Br J Cancer; 2004 May; 90(9):1733-9. PubMed ID: 15150604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
    Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
    Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.